Nucleoside analogs such as gemcitabine and 5-fluorouracil are currently the cornerstone of chemotherapy in patients with pancreatic ductal adenocarcinoma (PDAC). Decreased drug transport into tumor cells that may be caused by low expression of membrane proteins, such as solute carrier transporters, represents one of the principal mechanisms of chemotherapy resistance. Individual diversity of multidrug resistance is the major challenge limiting the success of anticancer treatment. Novel biomarkers and pharmacogenomic approaches could further optimize treatment algorithms leading to better survival and lower treatment toxicity in PDAC patients. In this review, the most promising predictive biomarkers from the solute carrier transporter family of membrane transporters and the potential applications for PDAC therapy with nucleoside analogues are summarized.

Department of Oncology Palacky University Medical School and Teaching Hospital Olomouc Czech Republic

Citace poskytuje Crossref.org

DNA Repair Pathway in Ovarian Cancer Patients Treated with HIPEC

SLC46A1 Haplotype with Predicted Functional Impact has Prognostic Value in Breast Carcinoma

Use of Germline Genetic Variability for Prediction of Chemoresistance and Prognosis of Breast Cancer Patients